HK1217483A1 - 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物 - Google Patents

作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物

Info

Publication number
HK1217483A1
HK1217483A1 HK16105434.5A HK16105434A HK1217483A1 HK 1217483 A1 HK1217483 A1 HK 1217483A1 HK 16105434 A HK16105434 A HK 16105434A HK 1217483 A1 HK1217483 A1 HK 1217483A1
Authority
HK
Hong Kong
Prior art keywords
quinoline
amino
receptor agonists
carboxamide derivatives
carboxamide
Prior art date
Application number
HK16105434.5A
Other languages
English (en)
Inventor
羅摩克里希納.尼羅吉
阿尼爾.卡巴里.欣德
文卡特斯瓦盧.賈斯蒂
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of HK1217483A1 publication Critical patent/HK1217483A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
HK16105434.5A 2013-03-20 2016-05-12 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物 HK1217483A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (zh) 2013-03-20 2013-10-18

Publications (1)

Publication Number Publication Date
HK1217483A1 true HK1217483A1 (zh) 2017-01-13

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105434.5A HK1217483A1 (zh) 2013-03-20 2016-05-12 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物

Country Status (19)

Country Link
US (1) US9790211B2 (zh)
EP (1) EP2976337B1 (zh)
JP (1) JP6185650B2 (zh)
KR (1) KR101815307B1 (zh)
CN (1) CN105164119B (zh)
AP (1) AP2015008742A0 (zh)
AU (1) AU2013382944B2 (zh)
BR (1) BR112015024060A2 (zh)
CA (1) CA2907620C (zh)
DK (1) DK2976337T3 (zh)
EA (1) EA029365B1 (zh)
ES (1) ES2674993T3 (zh)
HK (1) HK1217483A1 (zh)
IN (1) IN2013CH01199A (zh)
MX (1) MX364929B (zh)
NZ (1) NZ712369A (zh)
SG (1) SG11201507763RA (zh)
WO (1) WO2014147636A1 (zh)
ZA (1) ZA201506804B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2734734T3 (es) * 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502273A (ja) * 1992-10-13 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−ht▲下4▼レセプターアンタゴニスト用複素環式エステルまたはアミド
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095902A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab A composition comprising a combination of receptor agonists and antagonists
DE602004009069T2 (de) 2003-06-19 2008-06-19 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidinbenzamide als 5ht4-antagonisten
US7964727B2 (en) 2003-11-24 2011-06-21 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-HT4 receptor agonistic activity
ATE457309T1 (de) * 2003-12-23 2010-02-15 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
ATE449092T1 (de) 2005-07-22 2009-12-15 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
RU2569733C2 (ru) * 2010-02-12 2015-11-27 Раквалиа Фарма Инк. Агонисты 5-нт4-рецепторов для лечения деменции
IN2012DN06631A (zh) 2010-02-16 2015-10-23 Pfizer

Also Published As

Publication number Publication date
ZA201506804B (en) 2016-07-27
MX364929B (es) 2019-05-14
US9790211B2 (en) 2017-10-17
CA2907620A1 (en) 2014-09-25
EA201591844A1 (ru) 2016-08-31
CN105164119A (zh) 2015-12-16
IN2013CH01199A (zh) 2015-08-14
EP2976337B1 (en) 2018-05-02
SG11201507763RA (en) 2015-10-29
US20160280694A1 (en) 2016-09-29
KR20160004274A (ko) 2016-01-12
AP2015008742A0 (en) 2015-09-30
EA029365B1 (ru) 2018-03-30
EP2976337A1 (en) 2016-01-27
CA2907620C (en) 2018-03-13
CN105164119B (zh) 2017-12-08
MX2015012350A (es) 2016-05-09
KR101815307B1 (ko) 2018-01-04
AU2013382944B2 (en) 2016-08-04
ES2674993T3 (es) 2018-07-05
DK2976337T3 (en) 2018-07-16
JP6185650B2 (ja) 2017-08-23
AU2013382944A1 (en) 2015-10-08
NZ712369A (en) 2016-11-25
WO2014147636A8 (en) 2014-12-04
BR112015024060A2 (pt) 2017-07-18
JP2016516089A (ja) 2016-06-02
WO2014147636A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1217294A1 (zh) '- '- '-氟- '-甲基取代的核苷衍生物
HRP20181141T1 (hr) Derivati purina kao agonisti cb2 receptora
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
SG11201605189YA (en) Imidazopyrazinone derivatives
IL245948B (en) 5–ht4 indazole compounds as receptor agonists
HK1213566A1 (zh) 新的四唑酮衍生物
HK1217483A1 (zh) 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211016